We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 773

USPTO Finds SureGene Personalized Medicine Treatment Unpatentable Under Mayo
  • Foley & Lardner LLP
  • USA
  • September 26 2017

In Ex Parte Timothy, the USPTO Patent Trial and Appeal Board (PTAB) affirmed the Examiner’s rejection of personalized medicine treatment claims. This


Celgene Notches Rare Win On PTAB Request For Rehearing
  • Foley & Lardner LLP
  • USA
  • September 20 2017

The recent decisions of the USPTO Patent Trial and Appeal Board (PTAB) granting Celgene’s requests for rehearing in parallel Inter Partes Review


CAFC Finds Harmless Error in USPTO Reliance On Doctrine of Inherency
  • Foley & Lardner LLP
  • USA
  • September 12 2017

In Southwire Co. v. Cerro Wire LLC, the Federal Circuit upheld the USPTO decision rendered in an inter partes reexamination proceeding that found


CAFC Vacates USPTO Single Reference Obviousness Rejection For Inadequate Showing Of Expectation of Success
  • Foley & Lardner LLP
  • USA
  • August 29 2017

In a split decision with Judge Lourie dissenting, the Federal Circuit vacated an obviousness rejection that had been affirmed in an ex parte appeal to


Federal Circuit Provides More Guidance On Biosimilar Patent Litigation
  • Foley & Lardner LLP
  • USA
  • August 22 2017

In Amgen Inc. v. Hospira, Inc., the Federal Circuit held that Amgen could not obtain discovery related to activities that might infringe a patent that


Federal Circuit Criticizes PTAB Reliance On Routine Testing
  • Foley & Lardner LLP
  • USA
  • August 15 2017

In Honeywell International, Inc. v. Mexichem Amanco Holdings S.A. DE C.V., the Federal Circuit vacated the decision of the USPTO Patent Trial and


A Look At The USPTO Patent Eligible Subject Matter Report
  • Foley & Lardner LLP
  • USA
  • August 8 2017

On July 24, 2017, the USPTO issued a 48-page report on Patent Eligible Subject Matter. The report summarizes key court decisions interpreting and


Fairness in Evaluation: Federal Circuit Remand Back to Board For Failure to Fully Consider Petitioner’s Arguments Against Motion to Amend
  • Foley & Lardner LLP
  • USA
  • August 2 2017

In Shinn Fu Company of America, Inc. et al. V. The Tire Hanger Corp., Slip Op. 2016-2250 (Fed. Cir. July 3, 1997) (non-precedential), the Federal


Federal Circuit Finds Regeneron Transgenic Mouse Patent Invalid For Inequitable Conduct With Intent Inferred From Litigation Misconduct
  • Foley & Lardner LLP
  • USA
  • August 1 2017

In a 38 page decision with a 19 page dissent by Judge Newman, the Federal Circuit determined that Regeneron’s transgenic mouse patent is


Federal Circuit Finds Velcade Patent Not Obvious Under Lead Compound Analysis
  • Foley & Lardner LLP
  • USA
  • July 25 2017

In Millennium Pharmaceuticals, Inc. v. Sandoz, the Federal Circuit reversed the district court decision that invalidated one of the Orange